GT201400167A - Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 - Google Patents

Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Info

Publication number
GT201400167A
GT201400167A GT201400167A GT201400167A GT201400167A GT 201400167 A GT201400167 A GT 201400167A GT 201400167 A GT201400167 A GT 201400167A GT 201400167 A GT201400167 A GT 201400167A GT 201400167 A GT201400167 A GT 201400167A
Authority
GT
Guatemala
Prior art keywords
mogat
bencil
inhibitors
new derivatives
sulfonamide
Prior art date
Application number
GT201400167A
Other languages
English (en)
Spanish (es)
Inventor
Pfeifer Lance Allen
Fernandez Maria Carmen
Gonzalez Garcia María Rosario
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47148691&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GT201400167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of GT201400167A publication Critical patent/GT201400167A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C311/05—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/65—One oxygen atom attached in position 3 or 5

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
GT201400167A 2012-01-31 2014-07-29 Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2 GT201400167A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261592717P 2012-01-31 2012-01-31
EP12382432 2012-11-06

Publications (1)

Publication Number Publication Date
GT201400167A true GT201400167A (es) 2015-05-28

Family

ID=47148691

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201400167A GT201400167A (es) 2012-01-31 2014-07-29 Nuevos derivados de bencil sulfonamida utiles como inhibidores de mogat-2

Country Status (27)

Country Link
US (1) US8575352B2 (enExample)
EP (1) EP2809651B1 (enExample)
JP (1) JP2015511232A (enExample)
KR (1) KR20140106750A (enExample)
CN (1) CN104066719B (enExample)
AP (1) AP2014007794A0 (enExample)
AR (1) AR089771A1 (enExample)
AU (1) AU2013215468A1 (enExample)
BR (1) BR112014018636A8 (enExample)
CA (1) CA2859995A1 (enExample)
CL (1) CL2014001861A1 (enExample)
CO (1) CO7010839A2 (enExample)
CR (1) CR20140322A (enExample)
DO (1) DOP2014000178A (enExample)
EA (1) EA201491276A1 (enExample)
ES (1) ES2590929T3 (enExample)
GT (1) GT201400167A (enExample)
HK (1) HK1199025A1 (enExample)
IL (1) IL233712A0 (enExample)
MA (1) MA35886B1 (enExample)
MX (1) MX2014008599A (enExample)
PE (1) PE20141679A1 (enExample)
PH (1) PH12014501711A1 (enExample)
SG (1) SG11201404106QA (enExample)
TW (1) TW201343629A (enExample)
WO (1) WO2013116075A1 (enExample)
ZA (1) ZA201404836B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
MX2014008604A (es) 2012-01-31 2014-08-22 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2.
CA2886831A1 (en) 2012-11-06 2014-05-15 Eli Lilly And Company Novel benzyl sulfonamide compounds useful as mogat-2 inhibitors
KR102722949B1 (ko) 2015-06-15 2024-10-28 엔엠디 파마 에이/에스 신경근 장애의 치료에 사용하기 위한 화합물
TWI782056B (zh) 2017-07-14 2022-11-01 日商鹽野義製藥股份有限公司 具有mgat2抑制活性的縮合環衍生物
US10385028B2 (en) 2017-12-14 2019-08-20 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11730714B2 (en) 2017-12-14 2023-08-22 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US12440477B2 (en) 2017-12-14 2025-10-14 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11147788B2 (en) 2017-12-14 2021-10-19 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
US11591284B2 (en) 2017-12-14 2023-02-28 Nmd Pharma A/S Compounds for the treatment of neuromuscular disorders
MX2021008050A (es) 2019-01-11 2021-08-05 Shionogi & Co Derivado de dihidropirazolopirazinona que tiene actividad inhibidora de monoacilglicerol aciltransferasa 2 (mgat2).

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1659113A1 (en) * 2004-11-08 2006-05-24 Evotec AG Inhibitors of 11beta-hydroxy steroid dehydrogenase type 1 (11beta-HSD1)
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
CN101087771A (zh) * 2004-11-10 2007-12-12 辉瑞大药厂 经取代n-磺酰基氨基苄基-2-苯氧基乙酰胺化合物
DE602005009017D1 (de) * 2004-11-10 2008-09-25 Pfizer Substituierte n-sulfonylaminobenzyl-2-phenoxyacetamidverbindungen
MX2009002527A (es) * 2006-09-08 2009-03-20 Pfizer Prod Inc Derivados de eter diarilico y usos de los mismos.
JPWO2008038768A1 (ja) 2006-09-28 2010-01-28 大日本住友製薬株式会社 二環性ピリミジン構造を有する化合物及びそれを含有する医薬組成物
CN101583593A (zh) * 2006-11-13 2009-11-18 辉瑞产品公司 二芳基、二吡啶基和芳基-吡啶基衍生物及其用途
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
AU2010216633A1 (en) 2009-02-23 2011-09-08 Msd K.K. Pyrimidin-4(3H)-one derivatives
US9073856B2 (en) 2012-01-23 2015-07-07 Eli Lilly And Company Phenyl methanesulfonamide derivatives useful as MGAT-2 inhibitors
MX2014008604A (es) 2012-01-31 2014-08-22 Lilly Co Eli Nuevos derivados de morofolinilo utiles como inhibidores de mogat-2.

Also Published As

Publication number Publication date
DOP2014000178A (es) 2014-08-31
BR112014018636A2 (enExample) 2017-06-20
US20130197039A1 (en) 2013-08-01
CL2014001861A1 (es) 2014-11-07
BR112014018636A8 (pt) 2017-07-11
EP2809651B1 (en) 2016-06-29
US8575352B2 (en) 2013-11-05
MX2014008599A (es) 2014-08-22
ES2590929T3 (es) 2016-11-24
EA201491276A1 (ru) 2014-10-30
CN104066719B (zh) 2016-08-24
HK1199025A1 (en) 2015-06-19
CN104066719A (zh) 2014-09-24
JP2015511232A (ja) 2015-04-16
CA2859995A1 (en) 2013-08-08
PE20141679A1 (es) 2014-11-08
TW201343629A (zh) 2013-11-01
AR089771A1 (es) 2014-09-17
AU2013215468A1 (en) 2014-07-10
ZA201404836B (en) 2017-08-30
SG11201404106QA (en) 2014-08-28
IL233712A0 (en) 2014-09-30
WO2013116075A1 (en) 2013-08-08
CO7010839A2 (es) 2014-07-31
MA35886B1 (fr) 2014-12-01
EP2809651A1 (en) 2014-12-10
CR20140322A (es) 2014-08-25
AP2014007794A0 (en) 2014-07-31
PH12014501711A1 (en) 2014-10-13
KR20140106750A (ko) 2014-09-03

Similar Documents

Publication Publication Date Title
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
CY1120703T1 (el) Ετεροκυκλικες ενωσεις και χρησεις αυτων
MX2020011449A (es) Oxiesteroles y metodos de uso de los mismos.
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY35242A (es) Inhibidores de fosfatidilinositol 3-quinasa
MX2016013689A (es) Compuestos 4-amino-imidazoquinolina.
UY35617A (es) Inhibidores de la fosfatidilinositol 3-quinasa
DOP2015000158A (es) Inhibidores de prmt5 y sus usos
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
ECSP15008851A (es) Compuestos heteroaromáticos como inhibidores de btk
UY36170A (es) Compuestos de dihidroisoquinolinona sustituida
UY35663A (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
BR112017013440A2 (pt) compostos de isoquinolina para o tratamento de hiv
CR20150472A (es) USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd
EA201401292A2 (ru) Новые тиенопиримидиновые производные, способ их получения и фармацевтические композиции, содержащие их
GT201300174A (es) Compuestos de indol o análogos de los mismos útiles para el tratamiento de la degeneración macular relacionada con la edad (dme)
MX2016001304A (es) Polimorfo de inhibidores de syk.
EA201590224A1 (ru) Имидазотриазинкарбонитрилы, используемые в качестве ингибиторов киназы
BR112016014020A8 (pt) moduladores de tetra-hidropiridopirazinas de gpr6.
ECSP15045801A (es) Inhibidores de la phd de 6–(5–hidroxi–1h–pirazol–1–il)nicotinamida
DOP2014000178A (es) Nuevos derivados de bencil sulfonamida útiles como inhibidores de mogat-2
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
CO2017009994A2 (es) Nuevos compuestos y derivados de sulfonimidoilpurinona para el tratamiento y profilaxis de infecciones víricas
BR112017013286A2 (pt) composto de isoxazolina, e, uso de um composto de isoxazolina.
DOP2014000177A (es) Nuevos derivados de morofolinilo útiles como inhibidores de mogat-2